+91-8668442535

Kaposi Sarcoma Market By Treatment (Chemotherapy, Immunotherapy, Highly Active Antiretroviral Therapy (HAART), Radiation Therapy, Surgical Procedures) - Growth, Future Prospects, And Competitive Analysis, 2017 -2025

Kaposi sarcoma is caused by the infection of a virus called Kaposi sarcoma-associated herpes virus (KSHV). The disease prevalence is varied around the globe; there are four types of Kaposi sarcoma, such as AIDS-KS, immunocompromised, classic or sporadic, and endemic. Technological advancements in drug delivery, such as targeted immunotherapy and nanomedicines, are utilized to facilitate the cytotoxic payload through the blood vessels in Kaposi sarcoma tumors, which usually develop from the cells that line the lymph or blood vessels.

For the purpose of this study, the global Kaposi sarcoma market is studied in terms of treatment types and geography. The drug classes studied in the report include chemotherapy, which is further categorized as "alkaloids and liposomal anthracyclines studied in the report include chemotherapy, which is further categorized as "alkaloids and liposomal anthracyclines," immunotherapy, HAART, radiation therapy, and surgical procedures. Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.The geographic segmentation of the global Kaposi sarcoma market is performed for the regions of North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.

Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.This report also includes qualitative assessment factors such as market dynamics (drivers, restraints, and opportunities) to have a good understanding of the current and anticipated trends in the global Kaposi sarcoma market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with a profile of key market players currently enjoying prominent positions in the global Kaposi sarcoma market. The key players profiled in this report are Aphios Corp., Cytori Therapeutics, Inc., Bristol-Myers Squibb Company, CytRx Corporation, Eli Lilly and Co., GlaxoSmithKline plc, F.Hoffman La-Roche, Inc., Johnson & Johnson, Merck & Co., Inc., and Pfizer, Inc.

Based on treatment types, the global Kaposi sarcoma market is categorized into:

  • Chemotherapy
  • Alkaloids
  • Liposomal Anthracyclines
  • Immunotherapy
  • Highly Active Antiretroviral Therapy (HAART)
  • Radiation Therapy
  • Surgical Procedures

The rising prevalence of AIDs-related Kaposi sarcoma, the increasing number of iatrogenically immunocompromised patients, and the urgent need for novel drug discovery in treating subtypes such as classic Kaposi sarcoma found in the Eastern Mediterranean region are driving the Kaposi sarcoma market. Furthermore, an increase in the number of diagnostic centers, as well as increased physician awareness of disease etiology, will propel Kaposi sarcoma's market penetration. In 2016, the highly active antiretroviral therapy (HAART) segment held the largest market share due to factors such as the rising prevalence of AIDS, as patients suffering from HIV infection are prone to developing Kaposi sarcoma, and the proactive government initiative such as the United States President's Emergency Plan for AIDS Relief (PEPFAR) to fight AIDS-KS.

Chemotherapy will be the fastest-growing segment throughout the forecast period of 2017–2025, primarily due to factors such as technological advancement in the drug formulation, e.g., paclitaxel nanosomal formulation utilized as a topical treatment for AIDS-KS, surpassing the drug biotransformation, which is toxic to liver cells. Promising pipeline with excellent bioequivalence studies such as AT-0918 (Cytori Therapeutics, Inc.). Aldoxorubicin (CytRx Corporation) utilizes an acid-sensitive linker that selectively binds to albumin to allow the cytotoxic payload to accumulate near the tumor and spare the surrounding healthy tissues. The major players in the Kaposi sarcoma market are Aphios Corp., Cytori Therapeutics, Inc., Bristol-Myers Squibb Company, CytRx Corporation, Eli Lilly and Co., GlaxoSmithKline plc, F. Hoffman-La Roche, Inc., Johnson & Johnson, Merck & Co., Inc., and Pfizer, Inc.

For the purpose of this study, the global Kaposi sarcoma market is categorized into the following regional and country-specific markets:

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • Germany
  • France
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • rest of Latin America

Middle East and Africa

  • GCC
  • Rest of the Middle East and Africa

In 2016, North America was found to be the largest market for Kaposi sarcoma. According to the American Cancer Society, in 2016, the occurrence rate of Kaposi sarcoma was 6 cases per million people. More prevalent in Afro-American men. The dominance of North America is mainly attributed to the presence of key drivers such as the rising prevalence of AIDS-KS, an affordable reimbursement scenario, and developed research and healthcare institutions. The market growth in Europe is mainly attributed to the presence of major pharmaceutical players involved in Kaposi's sarcoma research and rising public health awareness resulting in early disease diagnosis and treatment.

Asia Pacific was observed as the fastest-growing regional segment throughout the forecast period of 2017–2025. Factors that are anticipated to propel market growth are the increasing number of AIDS patients with Kaposi sarcoma complications, increasing disposable incomes, and a supportive regulatory environment for Kaposi sarcoma drug products. Moreover, factors such as developing health infrastructure and proactive government initiatives to fight AIDS-KS in the untapped market of remote areas with unmet medical needs are going to fuel the rapid growth of the Kaposi sarcoma market in Latin America, the Middle East, and Africa in the near future.

Frequently Asked Questions:

The market for Kaposi Sarcoma Market is expected to reach US$ 135.6 Mn By 2025.

The Kaposi Sarcoma Market is expected to see significant CAGR growth over the coming years, at 2.44%.

The report is forecasted from 2017-2025.

The base year of this report is 2016.

Aphios Corp., Cytori Therapeutics, Inc., Bristol-Myers Squibb Company, CytRx Corporation, Eli Lilly and Co., GlaxoSmithKline plc, F. Hoffman-La Roche, Inc., Johnson & Johnson, Merck & Co., Inc., and Pfizer, Inc. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Sep 2017
Category:  Pharmaceuticals
Report ID:   58687
Report Format:   PDF
Pages:   120
Rating:    4.8 (80)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support